Recent studies continue to highlight the cardiovascular benefits of semaglutide, originally developed for diabetes treatment but now recognized for its effectiveness in reducing mortality risks in overweight and obese individuals with heart disease. An analysis of the FLOW trial presented at the ESC Congress 2024 found that semaglutide led to an 18% reduction in cardiovascular events across various kidney disease severities. Additionally, substudies published in JACC reveal that semaglutide not only lowers all-cause and cardiovascular mortality but also decreases COVID-19 related deaths among patients with obesity and cardiovascular disease. Importantly, semaglutide's efficacy appears consistent across genders. Furthermore, a real-world study comparing oral and subcutaneous semaglutide formulations showed equivalent effectiveness in glucose control and weight management for patients with chronic kidney disease. The growing body of evidence underscores the potential of GLP-1 receptor agonists to revolutionize cardiovascular care.